portal hypertension
Conditions
Interventions
A:Carvedilol, orally taken for 7 days. The initial dosage is 12.5mg once daily, and the dosage is modulated for the target that the heart rate reduces below 55 per minute or the reduction > 20% of the
B:Carvedilol+Isosorbide Mononitrate Sustained Release Tablets, orally taken for 7days. The initial dosage of carvedilol is 12.5mg once daily, and ISMN 30mg daily. The dosage is modulated for the targe
Sponsors
Shandong Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Male and female aged 18 to 75 years old; 2. Able and willing to provide signed informed consent; 3. Cirrhosis; 4. Presence of endoscopcally proven esophagogastric varices; 5. Baseline hepatic venous pressure gradient(HVPG) >=10mmHg.
Exclusion criteria
Exclusion criteria: 1. Non-cirrhotic portal hypertension; 2. Child-pugh score >13; 3. Contraindications to carvedilol or ISMN; 4. Presence of severe systemic illness (cardiorespiratory failure, acrive sepsis, renal failure); 5. Previous pharmacological treatment (beta or alpha adrenergic blockers, nitrates); 6. Uncontrolled hepatic encephalopathy; 7. Pregnant or lactating women; 8. Patients who do not give informed consent.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| diameter of portal vein;mean artery pressure;velocity of portal vein flow;blood flow of portal vein;heart rate; | — |
Primary
| Measure | Time frame |
|---|---|
| HVP; | — |
Countries
China
Contacts
Public ContactChunqing Zhang
Outcome results
None listed